However, the presence of Aβ-containing extracellular plaques and hyperphosphorylated tau-containing intracellular neurofibrillary tangles (NFTs) in the brain with AD remains an indisputable hallmark [2], underscoring the rationale for targeting Aβ and tau in therapeutic strategies. This evidence concerns the gene MAPT and Alzheimer disease.